IMADetect®

DEVICE3 trials

Sponsors

Immatics US, Inc.

Conditions

CancerRecurrent CancerRecurrent Solid TumorsRefractory CancerRefractory Solid TumorsSolid TumorSolid Tumor, Adult

Phase 1

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

CompletedNCT03247309

Immatics US, Inc.Cancer, Recurrent Solid Tumors, Refractory Solid Tumors +1

Start: 2018-12-19End: 2023-09-18Updated: 2025-02-04

TCR-engineered T Cells in Solid Tumors: IMA202-101

CompletedNCT03441100

Immatics US, Inc.Cancer, Recurrent Cancer, Refractory Cancer +1

Start: 2019-05-02End: 2023-03-17Updated: 2025-02-04

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

RecruitingNCT03686124

Immatics US, Inc.Cancer, Recurrent Cancer, Refractory Cancer +1

Start: 2019-05-14End: 2032-06-01Target: 375Updated: 2026-05-13

Related Papers

Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer.

Journal of Clinical Oncology2026-05-27

Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma.

Journal of Clinical Oncology2026-05-27

Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.

Journal of Clinical Oncology2025-05-28

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Nature Medicine2025-04-0924 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Abstract PR018: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors

Molecular Cancer Therapeutics2023-12-0112 citations

713 The PRAME opportunity – high peptide copy numbers, homogenous expression and high prevalence to address a broad patient population across different solid cancers with TCR-based therapeutics

Regular and Young Investigator Award Abstracts2022-11-01

959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

2021-11-0117 citations

Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection

PROTEOMICS2018-03-0541 citations

Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC.

Journal of Clinical Oncology2018-02-104 citations